Literature DB >> 10653860

Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study.

L R Coia1, B D Minsky, B A Berkey, M J John, D Haller, J Landry, T M Pisansky, C G Willett, J P Hoffman, J B Owen, G E Hanks.   

Abstract

PURPOSE: A Patterns of Care Study examined the records of patients with esophageal cancer (EC) treated with radiation in 1992 through 1994 to determine the national practice processes of care and outcomes and to compare the results with those of clinical trials. PATIENTS AND METHODS: A national survey of 63 institutions was conducted using two-stage cluster sampling, and specific information was collected on 400 patients with squamous cell (62%) or adenocarcinoma (37%) of the thoracic esophagus who received radiation therapy (RT) as part of primary or adjuvant treatment. Patients were staged according to a modified 1983 American Joint Committee on Cancer staging system. Fifteen percent of patients had clinical stage (CS) I disease, 40% had CS II disease, and 30% had CS III disease. Twenty-six percent of patients underwent esophagectomy. Seventy-five percent of patients received chemotherapy; 84% of these received concurrent chemotherapy and radiation (CRT).
RESULTS: Significant variables for overall survival in multivariate analysis include the use of esophagectomy (risk ratio [RR] = 0.62), the use of chemotherapy (RR = 0.63), Karnofsky performance status (KPS) greater than 80 (RR = 0.61), CS I or II disease (RR = 0.66), and facility type (RR = 0.72). Age, sex, and histology were not significant. Preoperative CRT resulted in a nonsignificantly higher 2-year survival rate compared with definitive CRT alone (63% v 39%; P =.11), whereas 2-year survival by planned treatment rather than treatment given was 47.7% for preoperative CRT and 35.4% for definitive CRT (P =.23). Definitive CRT compared with definitive RT alone resulted in significantly higher 2-year survival (39% v 20.6%; P =.027) and lower 2-year local regional failure (30% v 57.9%; P =. 0031).
CONCLUSION: This study confirms the value of CRT in EC treatment. It indicates that the results obtained in practice settings nationwide are similar to those obtained in clinical trials and that KPS and the 1983 clinical staging system are useful prognostic indicators. The suggested value of esophagectomy and superiority of preoperative CRT over CRT alone in this study should be tested in a randomized trial.

Entities:  

Mesh:

Year:  2000        PMID: 10653860     DOI: 10.1200/JCO.2000.18.3.455

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Endoscopic palliative treatment for esophageal and gastric cancer: techniques, complications, and survival in a population-based cohort of 948 patients.

Authors:  A M Thompson; T Rapson; F J Gilbert; K G M Park
Journal:  Surg Endosc       Date:  2004-05-28       Impact factor: 4.584

Review 2.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

3.  64-element intraluminal ultrasound cylindrical phased array for transesophageal thermal ablation under fast MR temperature mapping: an ex vivo study.

Authors:  D Melodelima; R Salomir; C Mougenot; C Moonen; D Cathignol
Journal:  Med Phys       Date:  2006-08       Impact factor: 4.071

4.  Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit?

Authors:  R Semrau; S L Herzog; D Vallböhmer; M Kocher; A Hölscher; R-P Müller
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

5.  Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.

Authors:  Frederic Di Fiore; Stephane Lecleire; Olivier Rigal; Marie-Pierre Galais; Emmanuel Ben Soussan; Isabelle David; Bernard Paillot; Jacques-Henri Jacob; Pierre Michel
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

6.  Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.

Authors:  Nicholas W Choong; Ann M Mauer; Daniel C Haraf; Mark K Ferguson; Alan B Sandler; Kenneth A Kesler; Paul A S Fishkin; Rafat H Ansari; James Wade; Stuart A Krauss; David F Sciortino; Mitchell C Posner; Masha Kocherginsky; Philip C Hoffman; Livia Szeto; Everett E Vokes
Journal:  Med Oncol       Date:  2010-08-21       Impact factor: 3.064

7.  Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines.

Authors:  Satoshi Tabuchi; Soji Ozawa; Kazuo Koyanagi; Naoyuki Shigematsu; Atsushi Kubo; Masakazu Ueda; Yuko Kitagawa; Masaki Kitajima
Journal:  Exp Ther Med       Date:  2011-05-10       Impact factor: 2.447

8.  Clinical evaluation of oral Fructus bruceae oil combined with radiotherapy for the treatment of esophageal cancer.

Authors:  Guo-yong Shan; Song Zhang; Guo-wen Li; Yong-shun Chen; Xing-an Liu; Jian-kun Wang
Journal:  Chin J Integr Med       Date:  2011-12-03       Impact factor: 1.978

Review 9.  Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.

Authors:  Johannes Zacherl; Andreas Sendler; Hubert J Stein; Katja Ott; Marcus Feith; Raimund Jakesz; J Rüdiger Siewert; Ulrich Fink
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

10.  Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.

Authors:  Daniel King Hung Tong; Simon Law; Dora Lai Wan Kwong; Kwok Wah Chan; Alfred King Yin Lam; Kam Ho Wong
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.